Leah Sherwood
Articles by Leah Sherwood
The EC approval of luspatercept was based on results from the phase II BEYOND study.
The approval of the treatment provides patients with an alternative to a product that has historically been in shortage.
Molly Stoddart, RN, BSN, is a clinical research nurse on the multiple myeloma team at the Winship Cancer Institute at Emory.
ADX-2191 is a sterile, noncompounded intravitreal formulation of methotrexate.
The FDA is expected to make a final decision on the supplemental BLA for polatuzumab vedotin-piiq in DLBCL in early April.
MDS/AML are among independent predictors of COVID-19 treatment failure.
The FDA has approved an Investigational New Drug application for EP0042, a dual FLT-3 and aurora kinase inhibitor.
The OPTIMUM/MUKnine clinical trial aimed to reduce the risk of relapse before and after AHSCT in ultrahigh-risk MM.
AB-101 is an allogeneic, cryopreserved, ADCC-enhancing natural killer-cell therapy.
The new FDA decision follows its granting of Breakthrough Therapy Designation to elranatamab in November 2022.
The AACR Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome took place from January 23-25, 2023.
Advocates hope it will bring much-needed changes to patient care for complex cancers—including hematologic malignancies.
The study used natural language processing for computer-assisted review of electronic health records.
The research shows an emerging target for the development of novel CAR T-cell immunotherapies.
Ponatinib was more effective than imatinib when given with reduced-intensity chemotherapy in newly diagnosed Ph+ ALL.
The optical genome mapping platform will have clinical implications for patients with acute myeloid leukemia and MDS.
These results have potential implications for the long-term success of venetoclax therapy.
The EHA-EBMT 5th European CAR T-Cell Meeting was held February 9-11 in Rotterdam, Netherlands.
The results showed pembrolizumab was well tolerated, with 23.5% of patients achieving a complete response.
The study also found DDX41 germline variants explained approximately 80% of known germline predisposition to MNs in adults.
670 Madison Ave.
Manalapan, NJ 07726